Form 4: Enanta Pharma Officer Receives Equity Grants

Kathleen S. Capps, an officer at Enanta Pharmaceuticals, Inc., was granted restricted stock units and stock options.

Summary

• Kathleen S. Capps, Executive Director of Accounting, Controller (Principal Accounting Officer) at Enanta Pharmaceuticals, Inc. (ENTA), acquired 3,163 shares of common stock through a grant of Restricted Stock Units (RSUs) on November 25, 2025.
• These RSUs were granted under the Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan, with each RSU representing the contingent right to receive one share of common stock upon vesting.
• The RSUs will vest and settle with respect to 25% of the award on December 1, 2026, and in substantially equal annual installments over the next three anniversaries thereafter.
• Additionally, Ms. Capps acquired 6,325 stock options on November 25, 2025, with an exercise price of $13.66 per share and an expiration date of November 25, 2035.
• These stock options will become exercisable quarterly in substantially equal installments over four years from the grant date (November 25, 2025), subject to continued employment.
• Following these transactions, Ms. Capps beneficially owns 8,992 shares of common stock directly and 6,325 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The filing details routine executive compensation through equity grants, which is generally a positive for aligning management and shareholder interests. It does not contain any negative or unexpected information, nor does it provide significant new positive operational or financial news.

Positives

• The equity grants to a key executive align management's financial interests with those of shareholders, incentivizing long-term performance.
• The grants are made under an existing equity incentive plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend over several years, indicating a long-term incentive structure for the executive, contingent on continued employment and future performance.

Industry Context

Equity grants, including restricted stock units and stock options, are a common form of executive compensation in the biotechnology and pharmaceutical industries. They are designed to attract, retain, and motivate key personnel by linking their compensation to the company's stock performance and long-term success.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants are intended to align the interests of a key executive with those of shareholders, potentially leading to improved long-term company performance and value creation.
• Employees: The compensation structure for executives can influence overall employee morale and retention strategies, particularly for other key personnel.

Next Steps

• The Restricted Stock Units will vest in installments, with the first 25% vesting on December 1, 2026, and subsequent installments annually thereafter.
• The stock options will become exercisable quarterly over four years from the grant date, subject to the optionholder's continued employment.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, insider transaction, equity grant, restricted stock units, stock options, executive compensation, corporate governance